Bitcoin Updates: Saylor Remains Confident in Bitcoin, Driving Strategy's Aggressive Investment Despite Market Downturn
- Michael Saylor denies rumors of selling Strategy's 641,692 BTC ($22.5B) amid market selloff, reaffirming long-term accumulation strategy . - Bitcoin fell below $96,000 as MSTR dropped 35% YTD, but Saylor claims recent 487 BTC purchase shows accelerated buying. - Analysts call current BTC correction a "mid-cycle consolidation" phase, noting historical patterns from 2024-2025 market analysis. - Strategy's $20.29B unrealized gains and Saylor's "long-haul" stance highlight Bitcoin's perceived store-of-value
Michael Saylor, the executive chairman of
This rebuttal comes as both Bitcoin and Strategy’s stock (MSTR) encounter renewed selling pressure. Bitcoin dropped below $96,000 on November 14, representing a 6.95% decrease in the last 24 hours, while
Saylor’s remarks come amid speculation that Strategy, which owns 641,692 BTC (valued at about $22.5 billion), could sell part of its holdings to strengthen its balance sheet. The company’s market-to-net-asset value (mNAV) has
The speculation intensified after an X user claimed Strategy had sold 33,000 BTC, worth $3.2 billion. Saylor’s prompt denial, along with his consistent advocacy for Bitcoin’s long-term prospects, has helped reassure some investors. “Our commitment is for the long term,” he emphasized, reiterating his previous assertions that Bitcoin’s value will keep increasing despite short-term fluctuations
Elsewhere, overall market sentiment remains divided. U.S. spot Bitcoin ETFs saw $870 million in net withdrawals—the second-largest daily outflow ever—though most long-term investors have held firm
Strategy has accumulated its Bitcoin over five years at an average price of $74,079 per coin, resulting in $20.29 billion in unrealized profits
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin News Update: Crypto Fear Index Drops Sharply—Sign of Surrender or Spark for a Rebound?
- Crypto Fear & Greed Index hit 16, its lowest since February 2025, reflecting extreme bearish sentiment amid Bitcoin and altcoin sell-offs. - Technical indicators and on-chain data show Bitcoin below key moving averages, with 815,000 BTC sold by long-term holders in 30 days. - Analysts highlight $100,000 as critical support, warning further declines if broken, while some see panic-driven buying opportunities. - Technical patterns suggest potential rebounds to $120,000-$126,000 if support holds, contrastin
Bitcoin Updates: Crypto Confidence Wavers—Saylor Calms Fears as Bearish Trends Persist
- Michael Saylor denied rumors of MicroStrategy selling Bitcoin , calming panic after $5.7B in crypto transfers to new wallets triggered market volatility. - Arkham clarified the 43,415 BTC wallet movements as routine custody management, but shares fell 7.2% as investor anxiety over the firm's financial health persisted. - Bitcoin traded near its 50-week SMA at $97,000 amid $870M ETF outflows, with analysts warning of further underperformance against gold and tech stocks in 2025. - Corporate Bitcoin accumu
ZEC +10.72% Surge Attributed to Introduction of Privacy-Oriented Treasury
- Zcash (ZEC) surged 10.72% in 24 hours to $683.14, driven by Cypherpunk Technologies' $50M treasury acquiring 1.25% supply stake. - Winklevoss Capital's $58.88M private placement and institutional backing highlight Zcash's privacy-focused positioning as "encrypted bitcoin ." - Zcash's new Zashi Wallet swap feature and EU regulatory shifts boost demand for privacy-centric assets, while backtests show 30-day excess returns of +22.6% after large price surges. - Cypherpunk's plan to acquire 5% ZEC supply and
LUNA rises by 2.66% despite ongoing legal uncertainties and unstable market conditions
- LUNA rose 2.66% in 24 hours to $0.081, contrasting with 11.76% 7-day and 13.28% 1-month declines. - MoonLake faces class-action lawsuits over alleged misleading claims about its nanobody drug SLK's clinical advantages versus BIMZELX. - Technical analysis shows MLTX's short-term positive momentum after earnings misses, but risks rise beyond one-week holding periods.
